Eisai Revises Global Sales Strategy; Slashes U.S. Staff, Finds Ways To Retain Chinese Workers
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai Co., Ltd. is unable to meet all of the sales goals it set for its Dramatic Leap Plan, which probably comes as little surprise to most as the Japanese pharma struggles with patent losses of its blockbuster products, approval delays and R&D failures of key compounds. The company is responding by making its U.S. and European operations leaner, at the expense of hundreds of jobs, and stabilizing operations in emerging markets like China, where the company hopes to stem massive employee turnover by bringing staff to Japan for training
You may also be interested in...
Eisai, Morphotek Gain Biologics Manufacturing Capability With New Plant Opening
Eisai gains biologics capability from subsidiary Morphotek’s new biologics manufacturing plant, as Eisai ramps up in emerging markets and transitions itself in a post-Aricept patent world.
Eisai, Morphotek Gain Biologics Manufacturing Capability With New Plant Opening
Eisai gains biologics capability from subsidiary Morphotek’s new biologics manufacturing plant, as Eisai ramps up in emerging markets and transitions itself in a post-Aricept patent world.
Success Hinging On Single Platforms For Kissei, Dainippon Sumitomo, NanoCarrier and Eisai: Japan Earnings Roundup (Part 2)
A look at key products that could determine the year ahead for Japanese pharma.